pharmacokinetic properties of systemically active, 1629t
prophylaxis regimens and approximate costs, 1626t
Antihistamines, 440t, 711, 822t, 975, 976t
for allergic rhinitis, 432, 433t
for anaphylaxis, 687–688, 689t
for rhinitis, 436–437
and sleep, 1764, 1776
Antimalarials, 707
Antimicrobials, 1328–1330t
costs of therapy, 1335
dosing, 1335–1340
toxicities, 1331–1334
Antimotility drugs, 1461
Antimycotic pulse therapy, 1627
Antineoplastics, and lactation, 1003t
Antioxidants, 1265
as photoprotective agents, 853
Antiplatelet agents, 658
Antipseudomonal β-lactam, 460
Antipseudomonal penicillins, 674
Antipsychotics
for acute agitation, 1846
for acute mania, 1844–1845
fo
r
b
ip
o
la
r
d
e
p
r
e
s
s
io
n
,
1
8
3
7
,
1
8
4
7
fo
r
c
r
it
ic
a
lly
ill
p
a
t
ie
nt
s
,
1
2
0
8
a
n
d
lith
ium
,
1
8
4
3
t
A
n
t
i
p
y
r
e
t
i
c
s
,
1
6
6
5
A
n
t
i
r
e
t
r
o
v
i
r
a
l
t
h
e
r
a
p
y
(
A
R
T
)
,
9
9
6
A
n
t
i
s
p
a
s
m
o
d
i
c
s
,
1
1
8
5
fo
r
I
B
S
,
5
3
5
A
n
t
i
s
p
a
s
t
i
c
i
t
y
a
g
e
n
t
s
,
1
1
8
5
A
n
t
i
t
h
y
m
o
c
yt
e
g
l
o
b
u
l
i
n
(
A
T
G)
,
7
2
2
–
7
2
3
A
n
t
i
t
h
y
r
o
i
d
d
r
u
g
s
,
t
e
r
a
t
o
g
e
n
i
c
e
ffe
c
t
s
,
9
7
3
t
A
n
t
i
v
i
r
a
l
s
a
dv
e
r
s
e
e
ffe
c
t
s
o
f,
1
3
3
4
t
in
fe
b
r
ile
n
e
utr
op
e
nic
p
a
t
ie
nt
,
1
5
6
9
fo
r
H
B
V
,
1
6
7
7
in
immun
o
c
o
mp
r
o
mis
e
d
p
a
t
ie
nt
s
,
1
6
5
4–
1
6
5
5
A
n
z
e
m
e
t
(
s
e
e
D
o
l
a
s
e
t
r
o
n
)
A
p
i
d
r
a
(
s
e
e
I
n
s
u
l
i
n
g
l
u
l
i
s
i
n
e
)
A
p
i
x
a
b
a
n
,
1
3
0
7
t
fo
r
p
r
e
v
e
nt
io
n
o
f
s
tr
o
ke
,
3
1
7
–
3
1
8
fo
r
s
tr
o
ke
p
r
e
v
e
nt
io
n
,
1
7
8
fo
r
w
a
r
fa
r
in
th
e
r
a
p
y
,
2
0
0
A
p
o
k
y
n
(
s
e
e
A
p
o
m
o
rp
h
i
n
e
)
A
p
o
m
o
rp
h
i
n
e
(
A
p
o
k
y
n
)
,
1
2
5
1
t
,
1
2
5
4
t
,
1
2
6
2
A
p
r
a
c
l
o
n
i
d
i
n
e
(
I
o
p
i
d
i
n
e
)
,
1
1
5
2
A
p
r
e
m
i
l
a
s
t
fo
r
p
la
qu
e
p
s
o
r
ia
s
is
,
8
4
1
fo
r
P
s
A
,
8
4
3
A
p
r
e
p
i
t
a
n
t
(
E
m
e
n
d
)
,
1
2
8
,
4
7
2
t
,
9
4
2
t
fo
r
C
I
N
V
,
4
7
1
–
4
7
3
,
4
7
2
t
,
4
7
4
t
,
4
7
5
fo
r
P
O
N
V
,
4
7
8
t
A
p
ri
s
o
(
s
e
e
M
e
s
a
l
a
m
i
n
e
)
A
q
u
a
c
e
l
A
g
(
s
e
e
S
i
l
v
e
r
s
u
l
fa
d
i
azi
n
e
c
r
e
a
m
)
A
q
u
aD
E
K
c
h
e
wa
b
l
e
t
a
b
l
e
t
,
4
5
7
t
p. 2
2
9
1
p. 2
2
9
2
A
q
u
A
D
E
K
l
i
q
u
i
d
,
4
5
7
t
A
q
u
a
r
e
t
i
c
s
,
5
7
9
–
5
8
0
A
r
a
n
e
s
p
(
s
e
e
D
a
rb
e
p
o
e
t
i
n
a
l
fa)
A
R
B
s
(
s
e
e
A
n
g
i
o
t
e
n
s
i
n
r
e
c
e
p
t
o
r
b
l
o
c
k
e
r
s
(
A
R
B
s
)
)
A
r
fo
r
m
o
t
e
r
o
l
,
4
2
0
t
A
r
g
a
t
r
o
b
a
n
,
1
7
8
A
ri
p
i
p
r
az
o
l
e
(
A
b
i
l
i
fy)
,
1
2
6
7
,
1
7
3
9
,
1
7
9
7
t
,
1
7
9
9
t
fo
r
a
c
ut
e
a
g
it
a
t
io
n
,
1
8
4
6
fo
r
a
c
ut
e
ma
nia
,
1
8
4
4–
1
8
4
5
,
1
8
4
5
t
a
n
d
b
ip
o
la
r
d
e
p
r
e
s
s
io
n
,
1
8
4
7
fo
r
b
ip
o
la
r
dis
o
r
d
e
r
,
1
8
4
9
t
fo
r
d
e
v
e
lop
me
nt
a
l
dis
o
r
d
e
r
s
,
1
8
5
7
–
1
8
5
8
fo
r
dy
s
lip
id
e
mia
,
1
8
0
4
fo
r
hyp
e
rp
r
o
la
c
t
in
e
mia
,
1
8
0
3
fo
r
s
c
h
iz
op
hr
e
nia
,
1
7
8
9
,
1
7
9
1
t
,
1
7
9
2
,
1
7
9
3
,
1
7
9
3
t
A
ri
p
i
p
r
az
o
l
e
l
a
u
r
o
x
i
l
,
1
7
9
5
t
A
ri
p
i
p
r
az
o
l
e
m
o
n
o
h
y
d
r
a
t
e
,
1
7
9
5
t
Armodafinil, 1777, 1779
ARNI (see Angiotensin receptor-neprilysin inhibitor (ARNI))
Aromatase inhibitor (Letrozole), 959, 960, 1013, 1972
for endometriosis, 1020
for polycystic ovary syndrome, 1012t
Arsenic trioxide, 469t
for AML, 2027
ART (see Antiretroviral therapy (ART))
Artemisinin, 1695
Artesunate, 1696
Arylcycloalkylamines, 1885
Asacol HD (see Mesalamine)
Ascorbic acid (vitamin C), 657–658, 918, 942t, 961
for anemia, 1931
Asenapine (Saphris), 1797t, 1799t
for acute mania, 1845t
for bipolar disorder, 1849t
for hyperprolactinemia, 1803
for schizophrenia, 1790, 1791t
Asparaginase (Elspar), 469t, 1982t, 1996, 1996t
neurotoxicity of, 1985, 1985t
preparations, 2018
Aspirin, 220, 692, 694, 705, 870–871, 870t, 881, 887, 888t, 1307t, 1312, 1313–1314
for ACS, 238t
for AMI, 251
and clopidogrel, 1315
for diabetes, 167
for end-of-life care, 87
gastric damage, 490, 491
GERD and, 503t
hypertension and, 144
induced anaphylaxis, 694
for PAD, 167–168
for STEMI, 360
for stroke prophylaxis, 2242
toxicity from, 67–70
Astepro (see Azelastine)
Ataluren, 452
Atazanavir (ATV), 120t, 128, 942t, 1579t
Atenolol, 258, 688, 1271t, 1272, 2261t
in hypertension, 159t
for MI, 253
Atezolizumab, 469t
ATG (see Antithymocyte globulin (ATG))
Ativan (see Lorazepam)
Atomoxetine, 1856, 1868t, 1869–1870
Atorvastatin, 46t, 110t, 116, 117t, 120t, 130, 171, 258, 924, 942t
for prostate cancer, 2086
Atovaquone-proguanil (Malarone), 49, 1697t, 1700, 1701
Atovaquone suspension
for mild to moderate PJP, 1603–1604
for toxoplasmosis, 1606
Atracurium, 2198
Atropine, 321
for end-of-life care, 89
Atrovent (see Ipratropium bromide)
Attapulgite, 2161
ATV (see Atazanavir (ATV))
Augmentin, 1325t
for aerobic gram-positive cocci, 1326t
for gram-negative aerobes, 1327t
Auvi-Q, 446t
Avanafil, and ED, 2265
Avastin (see Bevacizumab)
Avelox (see Moxifloxacin)
Avobenzone, 821, 849t, 852
Avycaz, 1325t
Axitinib, 470t
AZA (see Azathioprine (AZA))
Azacitidine, 469t
Azactam (see Aztreonam)
Azathioprine (AZA), 56, 626, 709, 712t, 713t, 718, 720–721, 881, 883, 918t, 928
for inflammatory bowel disease, 521t, 523–524
for ophthalmopathy, 1067
therapy for Wegener granulomatosis, 628
Azelaic acid, for comedonal acne, 827
Azelastine (Optivar), 437, 439t, 440t, 441t, 1165
for allergic rhinitis, 432
Azelastine HCl (Dymista), 441t
Azilsartan medoxomil, for hypertension, 154t
Azithromycin (Zithromax), 460, 690, 927, 1325t, 1326t, 1720, 1727
adverse effects of, 1332t
for Campylobacter infection, 1459
for chronic asthma, 399
for MAC, 1619
for nongonococcal urethritis, 1515
for travelers’ diarrhea, 1461t
for typhoid fever, 1456
Azole antifungals, 1624, 1625, 1639
drug interactions, 1639
risk factor C, 1628
for VVC, 1525
Azopt (see Brinzolamide)
Aztreonam (Azactam), 463, 1326t
for aerobic gram-positive cocci, 1326t
for anaerobes, 1328t
for CAPD-associated peritonitis, 1476t
for CNS infections, 1373t
for cystic fibrosis, 461t
dosing of, 1336t
for gram-negative aerobes, 1327t
for skin and soft tissue infections, 1550
for UTI, 1497t
Azulfidine (see Sulfasalazine)
B
Bacampicillin (Spectrobid), 1326t
Bacillus Calmette-Guérin vaccine, 1616
Bacitracin, 819
Baclofen, 1186t, 1224
B
a
c
t
ri
m
(
s
e
e
T
ri
m
e
t
h
o
p
ri
m
-
s
u
l
fa
m
e
t
h
o
x
az
o
l
e
)
B
a
l
s
a
l
azi
d
e
,
5
2
1
t
,
5
2
3
t
B
a
l
s
a
m
o
f
P
e
r
u
,
8
2
2
t
B
a
rb
i
t
u
r
a
t
e
s
,
9
4
2
t
(
s
e
e
a
l
s
o
S
e
d
a
t
i
v
e
s
)
GE
R
D
a
n
d
,
5
0
3
t
B
a
rl
e
y
m
a
l
t
e
x
t
r
a
c
t
,
2
1
5
9
t
B
a
s
i
l
i
x
i
m
a
b
,
7
2
3
B
az
e
d
o
x
i
fe
n
e
(
B
ZA
)
,
1
0
3
5
B
C
G
(
B
a
c
i
l
l
e
C
a
l
m
e
t
t
e
-
Gu
é
ri
n
)
v
a
c
c
i
n
e
,
1
4
2
7
B
E
A
C
O
P
P
,
fo
r
H
L
,
2
0
4
1
B
e
c
l
o
m
e
t
h
a
s
o
n
e
fo
r
a
lle
r
g
ic
r
h
init
is
,
4
4
2
fo
r
e
n
d
-
o
flife
c
a
r
e
,
8
7
B
e
c
l
o
m
e
t
h
a
s
o
n
e
d
i
p
r
o
p
i
o
n
a
t
e
(
B
e
c
o
n
a
s
e
A
Q
)
,
4
4
1
t
fo
r
B
P
D
,
2
1
7
6
B
e
c
o
n
a
s
e
A
Q
(
s
e
e
B
e
c
l
o
m
e
t
h
a
s
o
n
e
d
i
p
r
o
p
i
o
n
a
t
e
)
B
e
l
a
t
a
c
e
p
t
,
7
2
2
B
e
l
i
m
u
m
a
b
,
7
1
0
–
7
1
1
,
7
1
0
t
,
7
1
2
t
,
7
1
3
t
B
e
l
s
o
m
r
a
(
s
e
e
S
u
v
o
r
e
x
a
n
t
)
B
e
l
v
i
q
(
s
e
e
L
o
r
c
a
s
e
ri
n
)
B
e
n
a
d
ryl
(
s
e
e
D
i
p
h
e
n
h
y
d
r
a
m
i
n
e
)
B
e
n
az
e
p
ri
l
in
hyp
e
r
t
e
n
s
io
n
,
1
5
3
t
fo
r
v
a
s
c
ula
r
d
e
me
nt
ia
,
2
2
4
2
B
e
n
d
a
m
u
s
t
i
n
e
(
T
r
e
a
n
d
a)
fo
r
C
L
L
,
2
0
3
4
drug
int
e
r
a
c
t
io
n
w
ith
s
mo
kin
g
,
1
9
0
6
t
B
e
n
d
a
m
u
s
t
i
n
e
,
4
6
9
t
,
2
0
4
0
t
B
e
n
d
a
m
u
s
t
i
n
e
p
l
u
s
ri
t
u
x
i
m
a
b
(
B
R
)
,
2
0
3
4
B
e
n
z
a
t
h
i
n
e
p
e
n
i
c
i
l
l
i
n
G,
1
5
1
9
–
1
5
2
0
t
B
e
n
z
o
d
i
az
e
p
i
n
e
s
,
9
4
2
t
,
1
2
1
4
,
1
2
2
4
,
1
7
3
8
t
,
1
7
9
0
(
s
e
e
a
l
s
o
S
e
d
a
t
i
v
e
s
)
a
b
u
s
e
a
n
d
d
e
p
e
n
d
e
n
c
e
,
1
7
5
4
,
1
7
7
1
–
1
7
7
3
fo
r
a
c
ut
e
a
g
it
a
t
io
n
,
1
8
4
6
a
dv
e
r
s
e
e
ffe
c
t
s
,
1
7
4
1
fo
r
a
g
it
a
t
e
d
b
e
h
a
v
io
r
s
,
2
2
4
3
fo
r
A
ka
th
is
ia
,
1
7
9
9
a
lc
o
h
o
l
w
ith
dr
a
w
a
l,
1
8
9
4
a
n
d
a
nt
e
r
o
gr
a
d
e
a
mn
e
s
ia
,
1
7
4
1
b
r
e
a
s
t
milk
,
1
7
4
4
v
s. b
u
s
p
ir
o
n
e
,
1
7
4
6
c
linic
a
l
p
r
o
file
s
o
f,
1
7
3
7
t
C
N
S
s
t
imula
nt
s
,
1
8
8
3
a
n
d
c
o
gnit
iv
e
imp
a
ir
me
nt
,
1
7
4
1
fo
r
c
r
it
ic
a
lly
ill
p
a
t
ie
nt
s
,
1
2
0
8
fo
r
d
e
p
r
e
s
s
iv
e
dis
o
r
d
e
r
s
,
1
8
1
5
t
drug
int
e
r
a
c
t
io
n
,
1
7
4
3
w
ith
s
mo
kin
g
,
1
9
0
7
t
dur
a
t
io
n
o
f
tr
e
a
tme
nt
,
1
7
4
2
a
n
d
fa
lls
,
1
7
4
1
p. 2
2
9
2
p. 2
2
9
3
a
n
d
GA
B
A
-
A
r
e
c
e
p
t
o
r
s
,
1
7
3
9
for GAD, 1736
GERD and, 503t
induced sedation, management of, 1744
and lactation, 1776
LSD, 1886
for LTCF, 2229
mechanism of action, 1736–1737
for panic disorder, 1748
physiological factors influencing, 1744
for PMDD, 1025
and pregnancy, 1776
and respiratory depression, 1741
for SAD, 1751
for schizophrenia, 1785
sedative-hypnotics, 1881
and sleep, 1764, 1776, 1861
tolerance of, 1771–1773
use during lactation, 1743–1744
use in pregnancy, 1743–1744
withdrawalsyndrome, management of, 1742–1743
Benzoic acid, 1626
Benzophenones, 849t, 852
Benzoyl peroxide, for maculopapular acne, 828–829
Benzphetamine, 762
Benztropine (Cogentin), 1250t
for Akathisia, 1800t
for Parkinsonism, 1799
Benzyl alcohol, 822t
Bepotastine (Bepreve), 439t, 1165
Bepreve (see Bepotastine)
β-adrenergic agonists, 992
β-adrenergic blockers
for Akathisia, 1799
for patients with CKD, 617
for vascular dementia, 2242
β-adrenergic blocking agents, 313
β-adrenergic receptor blockers, 1061, 1751–1752
β-blockers, 544, 549–550, 942t
for ACS, 238t, 246, 257–258
adrenergic blocking agents, 271
alcohol withdrawal, 1896
benefits of, 257–258
CAD and, 214
carvedilol vs. metoprolol, 288–289
in HFrEF, 287–289
in HTN, 295
for hypertension, 140, 149t, 159t
metoprolol vs. carvedilol, 288–289
for MI, 257–258
in severe heart failure, 289
teratogenic effects, 973t
for thyroid storm, 1067–1068
β-hydroxy-β-methylglutaryl-CoA (HMG-CoA), 247
β-lactam, 455, 460–461, 697–698, 1564
adverse effects of, 1332t
and aminoglycoside, 1563
antibiotics, 460–461
double combinations, 1563
for febrile neutropenia, 1563
Betamethasone, 994
β2
-adrenergic agonists, 503t
β2
No comments:
Post a Comment
اكتب تعليق حول الموضوع